| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
5-Dehydroepisterol functions as a substrate and intermediate in the steroid biosynthesis pathway, specifically in the conversion of episterol to 24-methylenecholesterol. It is generated from episterol through the action of C-5 sterol desaturase (also known as ergosterol biosynthesis enzyme). Subsequently, 5-Dehydroepisterol is converted into 24-methylenecholesterol by the action of 7-dehydrocholesterol reductase (DHCR7). This compound does not have a traditional pharmacological target but serves as a metabolic intermediate in sterol synthesis.
|
|---|---|
| ln Vitro |
5-Dehydroepisterol exhibits antifungal activities as demonstrated in biological assays against various fungal strains. As an episterol derivative, it plays a crucial role in maintaining the structural integrity of fungal cell membranes. Its biological functions are primarily related to its role as a biosynthetic precursor to other essential sterols rather than direct enzyme inhibition. The compound is known to be an important intermediate linking episterol to downstream sterol products in the biosynthetic cascade.
|
| ln Vivo |
The in vivo activity of 5-Dehydroepisterol relates to its function as an intermediate in endogenous sterol biosynthesis pathways. In living organisms, it is transiently produced and rapidly converted to downstream products by metabolic enzymes. Its antifungal effects, when observed, are likely attributable to the disruption of normal sterol homeostasis rather than direct toxicity. The compound is naturally present in minute quantities in cells actively synthesizing sterols for membrane production and hormone generation.
|
| Enzyme Assay |
A non-cellular enzyme activity assay can be performed to study C-5 sterol desaturase activity. Recombinant C-5 sterol desaturase enzyme (e.g., human SC5D or yeast ERG3) is incubated with its substrate episterol (or 24-methylenecycloartenol) in assay buffer containing NADPH or other redox cofactors. After incubation, the reaction mixture is extracted with organic solvent and analyzed by HPLC or LC-MS to quantify the production of 5-Dehydroepisterol. Inhibition of the enzyme can be assessed by measuring reduced product formation.
|
| Cell Assay |
Cellular assays studying 5-Dehydroepisterol involve culturing sterol auxotrophic yeast strains or mammalian cells in sterol-depleted media. Cells are treated with the compound or with sterol biosynthesis inhibitors (e.g., azole antifungals that block CYP51) to alter endogenous 5-Dehydroepisterol levels. Following treatment, cellular sterols are extracted using organic solvents (hexane/isopropanol), derivatized if necessary, and analyzed by gas chromatography-mass spectrometry (GC-MS) or LC-MS to quantify 5-Dehydroepisterol accumulation relative to other sterol intermediates.
|
| Animal Protocol |
In vivo metabolic studies of 5-Dehydroepisterol are conducted using rodent models or genetically modified yeast. Animals are administered sterol biosynthesis inhibitors (e.g., triazoles) by oral gavage at therapeutic doses. Following treatment, tissues such as liver and skin are harvested, and sterols are extracted and analyzed by GC-MS or LC-MS/MS. The accumulation of 5-Dehydroepisterol relative to other intermediates indicates inhibition of downstream conversion steps. Alternatively, radiolabeled precursors such as [14C]-acetate are administered to track de novo sterol biosynthesis.
|
| ADME/Pharmacokinetics |
As an endogenous metabolic intermediate, 5-Dehydroepisterol is not administered as a drug and therefore has no independent pharmacokinetic profile. In vivo, it is produced transiently within cells during sterol biosynthesis and is rapidly metabolized to downstream products (e.g., 24-methylenecholesterol) by 7-dehydrocholesterol reductase. Its concentration reflects the activity of the sterol biosynthesis pathway rather than absorption or distribution parameters. The compound is lipophilic and resides within cellular membranes as part of the sterol pool.
|
| Toxicity/Toxicokinetics |
As a naturally occurring sterol intermediate found in minute quantities in mammalian cells, 5-Dehydroepisterol does not possess intrinsic toxicity when present at physiological levels. Toxicological studies of the compound itself are not available as it is not a drug candidate. However, accumulation of 5-Dehydroepisterol has been observed as a biomarker of sterol biosynthesis dysfunction caused by certain drugs. For example, in patients taking triazole antifungal agents that inhibit CYP51, altered sterol profiles including 5-Dehydroepisterol changes occur, but these are pharmacodynamic markers rather than toxic events.
|
| Additional Infomation |
Ergoster-5,7,24(28)-trien-3β-ol is a 3β-sterol with double bonds at positions 5 and 7 and a methylene group at position 24. It is a metabolite of Saccharomyces cerevisiae and Saccharomyces cerevisiae. It is a 3β-sterol, Δ(5),Δ(7)-sterol, and 3β-hydroxy-Δ(5)-sterol compound. Its function is related to 5α-ergosterane. 5-Dehydroepiandrosterol has been reported in Phycomyces blakesleeanus, Axinella cannabina, and Eutreptia viridis, and relevant data are available. Ergoster-5,7,24(28)-trien-3β-ol is a metabolite found or produced in Saccharomyces cerevisiae.
5-Dehydroepisterol (CAS# 23582-83-4) is a research-grade reference standard used for analytical method development and metabolic studies of sterol biosynthesis pathways. It is a naturally occurring sterol intermediate found in various organisms including fungi, plants, and animals. The compound has a molecular weight of 396.65 and molecular formula C2₈H44O. It is not a therapeutic drug and has no approved indications. Research applications include studying cholesterol and ergosterol biosynthesis, investigating sterol metabolism disorders, and characterizing enzyme activities such as C-5 sterol desaturase and 7-dehydrocholesterol reductase. |
| Molecular Formula |
C₂₈H₄₄O
|
|---|---|
| Molecular Weight |
396.65
|
| Exact Mass |
396.339
|
| CAS # |
23582-83-4
|
| PubChem CID |
10894570
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
7.474
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
712
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(C)C(=C)CCC(C)C1CCC2C1(CCC3C2=CC=C4C3(CCC(C4)O)C)C
|
| InChi Key |
ZEPNVCGPJXYABB-LOIOQLKMSA-N
|
| InChi Code |
InChI=1S/C28H44O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h9-10,18,20,22,24-26,29H,3,7-8,11-17H2,1-2,4-6H3/t20-,22+,24-,25+,26+,27+,28-/m1/s1
|
| Chemical Name |
(3S,9S,10R,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| Synonyms |
5Dehydroepisterol; 5 Dehydroepisterol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~1 mg/mL (~2.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5211 mL | 12.6056 mL | 25.2111 mL | |
| 5 mM | 0.5042 mL | 2.5211 mL | 5.0422 mL | |
| 10 mM | 0.2521 mL | 1.2606 mL | 2.5211 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
